HealthBioNTech halts mRNA colorectal cancer vaccine trial after safety review

BioNTech said it will end a mid-stage trial of its experimental mRNA cancer vaccine after an independent committee concluded the treatment was unlikely to extend the lives of colorectal cancer patients. The company’s U.S.-listed shares fell 7.5% on Friday.

BioNTechmRNA vaccinecolorectal cancerclinical trial

RReuters★★★☆☆2026-08-28 17:50Original